Cargando…
Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
In recent years, it has come a long way in the diagnosis, treatment, and follow-up of prostate cancer. Beside this, it was argued that definitive treatments could cause overtreatment, particularly in the very low, low, and favorable risk group. When alternative treatment and follow-up methods are be...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337958/ https://www.ncbi.nlm.nih.gov/pubmed/30178774 http://dx.doi.org/10.4103/aja.aja_64_18 |
_version_ | 1783388369752948736 |
---|---|
author | Demirel, Cihan H Altok, Muammer Davis, John W |
author_facet | Demirel, Cihan H Altok, Muammer Davis, John W |
author_sort | Demirel, Cihan H |
collection | PubMed |
description | In recent years, it has come a long way in the diagnosis, treatment, and follow-up of prostate cancer. Beside this, it was argued that definitive treatments could cause overtreatment, particularly in the very low, low, and favorable risk group. When alternative treatment and follow-up methods are being considered for this group of patients, active surveillance is seen as a good alternative for patients with very low and low-risk groups in this era. However, it has become necessary to find other alternatives for patients in the favorable risk group or patients who cannot adopt active follow-up. In the light of technological developments, the concept of focal therapy was introduced with the intensification of research to treat only the lesioned area instead of treating the entire organ for prostate lesions though there are not many publications about many of them yet. According to the initial results, it was understood that the results could be good if the appropriate focal therapy technique was applied to the appropriate patient. Thus, focal therapies have begun to find their “middle ground” place between definitive therapies and active follow-up. |
format | Online Article Text |
id | pubmed-6337958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63379582019-02-14 Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? Demirel, Cihan H Altok, Muammer Davis, John W Asian J Androl Invited Review In recent years, it has come a long way in the diagnosis, treatment, and follow-up of prostate cancer. Beside this, it was argued that definitive treatments could cause overtreatment, particularly in the very low, low, and favorable risk group. When alternative treatment and follow-up methods are being considered for this group of patients, active surveillance is seen as a good alternative for patients with very low and low-risk groups in this era. However, it has become necessary to find other alternatives for patients in the favorable risk group or patients who cannot adopt active follow-up. In the light of technological developments, the concept of focal therapy was introduced with the intensification of research to treat only the lesioned area instead of treating the entire organ for prostate lesions though there are not many publications about many of them yet. According to the initial results, it was understood that the results could be good if the appropriate focal therapy technique was applied to the appropriate patient. Thus, focal therapies have begun to find their “middle ground” place between definitive therapies and active follow-up. Medknow Publications & Media Pvt Ltd 2019 2018-08-31 /pmc/articles/PMC6337958/ /pubmed/30178774 http://dx.doi.org/10.4103/aja.aja_64_18 Text en Copyright: © The Author(s)(2018) http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Invited Review Demirel, Cihan H Altok, Muammer Davis, John W Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
title | Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
title_full | Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
title_fullStr | Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
title_full_unstemmed | Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
title_short | Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
title_sort | focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? |
topic | Invited Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337958/ https://www.ncbi.nlm.nih.gov/pubmed/30178774 http://dx.doi.org/10.4103/aja.aja_64_18 |
work_keys_str_mv | AT demirelcihanh focaltherapyforlocalizedprostatecanceristhereamiddlegroundbetweenactivesurveillanceanddefinitivetreatment AT altokmuammer focaltherapyforlocalizedprostatecanceristhereamiddlegroundbetweenactivesurveillanceanddefinitivetreatment AT davisjohnw focaltherapyforlocalizedprostatecanceristhereamiddlegroundbetweenactivesurveillanceanddefinitivetreatment |